Vvax 001
Alternative Names: rSFVeE6,7; Semliki Forest Virus Based Cancer Vaccine; SFVeE6,7; Vvax-001Latest Information Update: 30 Nov 2022
At a glance
- Originator ViciniVax
- Developer University of Groningen
- Class Cancer vaccines; Papillomavirus vaccines
- Mechanism of Action Human papillomavirus E6 protein inhibitors; Human papillomavirus E7 protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Cervical intraepithelial neoplasia
Most Recent Events
- 30 Nov 2022 Vvax 001 is still in phase II trials for Cervical intraepithelial neoplasia in Netherlands (IM) (EudraCT2019-004050-29)
- 30 Mar 2020 Phase-II clinical trials in Cervical intraepithelial neoplasia in Netherlands (IM) (EudraCT2019-004050-29)
- 28 Feb 2020 No recent reports of development identified for phase-I development in Cervical-intraepithelial-neoplasia in Netherlands (IM, Injection)